174482-98-5 Usage
Uses
Used in Pharmaceutical Industry:
4-(2-chloroisonicotinoyl)morpholine is used as a precursor in the synthesis of various pharmaceutical compounds for its potential to contribute to the development of new drugs with antitumor and antitubercular properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-(2-chloroisonicotinoyl)morpholine is utilized as a subject of study for its potential biological activity, with the aim of understanding its mechanisms of action and optimizing its therapeutic potential.
Used in Antitumor Applications:
4-(2-chloroisonicotinoyl)morpholine is explored as an antitumor agent, leveraging its potential to interfere with cancer cell growth and proliferation, offering a new avenue for cancer treatment.
Used in Antitubercular Applications:
4-(2-chloroisonicotinoyl)morpholine is also considered for its antitubercular properties, suggesting a possible role in the development of new treatments for tuberculosis, a disease that requires novel therapeutic approaches to combat drug-resistant strains.
Check Digit Verification of cas no
The CAS Registry Mumber 174482-98-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,4,8 and 2 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 174482-98:
(8*1)+(7*7)+(6*4)+(5*4)+(4*8)+(3*2)+(2*9)+(1*8)=165
165 % 10 = 5
So 174482-98-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H11ClN2O2/c11-9-7-8(1-2-12-9)10(14)13-3-5-15-6-4-13/h1-2,7H,3-6H2
174482-98-5Relevant academic research and scientific papers
SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS
-
Page/Page column 31, (2010/02/11)
The invention relates to compounds of formula (I) prodrugs thereof, and the pahrmaceutically acceptabel salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
-
Page/Page column 13, (2010/02/08)
The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1, and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
